title: Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
abstract: OBJECTIVE
  A phase II study of antineoplaston A10 and AS2-1 was conducted to evaluate the antineoplastic activity in patients with recurrent diffuse intrinsic brain stem glioma.
  
  
  METHODS
  This report describes the results of treatment of the first 12 patients admitted to the study. Patients received escalating doses of antineoplaston A10 and AS2-1 by intravenous bolus injections. The median duration of treatment was 6 months and the average dosage of antineoplaston A10 was 11.3 g/kg/day and of antineoplaston AS2-1 0.4 g/kg/day. Responses were assessed by gadolinium-enhanced magnetic resonance imaging of the head.
  
  
  RESULTS
  Of ten evaluable patients, complete response was determined in two cases (20%), partial response in three (30%), stable disease in three (30%) and progressive disease in two (20%). Survival at 2 years was 33.3%. Currently, of all 12 patients, two (17%) were alive and tumour free for over 5 years since initial diagnosis; one was alive for more than 5 years, and another for more than 4 years from the start of treatment. Only mild and moderate toxicities were observed, which included three cases of skin allergy, two cases of anaemia, fever and hypernatraemia, and single cases of agranulocytosis, hypoglycaemia, numbness, tiredness, myalgia and vomiting.
  
  
  CONCLUSIONS
  The results of this study compared favourably with the responses of patients treated with radiation therapy and chemotherapy. The study continues with accrual of additional patients.
authors.affiliation: Department of Internal Medicine, Burzynski Clinic, Houston, Texas, USA. info@burzynskiclinic.com
authors.forename: Stanislaw R
authors.initials: SR
authors.lastname: Burzynski
authors.forename: Robert I
authors.initials: RI
authors.lastname: Lewy
authors.forename: Robert A
authors.initials: RA
authors.lastname: Weaver
authors.forename: Maxwell L
authors.initials: ML
authors.lastname: Axler
authors.forename: Tomasz J
authors.initials: TJ
authors.lastname: Janicki
authors.forename: Gabor F
authors.initials: GF
authors.lastname: Jurida
authors.forename: Jaroslaw K
authors.initials: JK
authors.lastname: Paszkowiak
authors.forename: Barbara G
authors.initials: BG
authors.lastname: Szymkowski
authors.forename: Mohammad I
authors.initials: MI
authors.lastname: Khan
authors.forename: Mark
authors.initials: M
authors.lastname: Bestak
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044482:Benzeneacetamides / Q000009:adverse effects* / Q000627:therapeutic use*; D020295:Brain Stem Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002533:Cerebral Angiography; D002648:Child; D004338:Drug Combinations; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality; D005973:Glutamine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D017567:Karnofsky Performance Status; D010648:Phenylacetates / Q000009:adverse effects* / Q000627:therapeutic use*; D010881:Piperidones / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment / Q000379:methods; D013997:Time Factors
chemical_list: D044482:Benzeneacetamides; D004338:Drug Combinations; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine; C092038:antineoplaston AS 2-1; C052091:antineoplaston A10